The global resurgence of tuberculosis (TB) over the past decades has been fueled by emerging drug resistance, co-infection with increasingly prevalent HIV and decreasing investments in public health systems. These challenges call for innovative, strategic approaches and more efficient, cost-effective programs. TB CARE I is a coalition of seven international TB control organizations, each with offices in most of the TB-priority countries for the U.S. Agency for International Development (USAID).
FHI 360 is the lead coordinating partner in Cambodia, Mozambique and Zambia and a collaborating partner in Indonesia and Nigeria. The program focuses on specific technical areas, including early case detection, improved laboratory capacity, management of drug-resistant TB, TB/HIV co-infection and health systems strengthening. FHI 360 and TB CARE I assist countries to move toward universal access to TB treatment by working with communities most at risk to reduce morbidity and mortality through increased case detection and treatment.
In Mozambique, FHI 360 combines TB and malaria interventions, allowing gains in efficiency and the strengthening of both programs. The project contributes to improved early detection, diagnosis and treatment through investments at the community level to identify people with TB and provide early treatment referrals. Laboratory strengthening efforts recently brought two new regional laboratories and an online laboratory into operation.
The Nigeria program made multiple contributions to the improved management of multidrug-resistant TB patients, with the establishment of a 40-bed multidrug-resistant TB ward at two hospitals: the Lagos State Mainland Hospital in South West Nigeria and at the Infectious Disease Hospital, Kano State, in North West Nigeria.
TB CARE I is currently active in the following countries: Cambodia, Indonesia, Kenya, Mozambique, Nigeria and Zambia.